[HTML][HTML] Prognostic significance of immune-related adverse events in metastatic renal cell carcinoma patients treated with immune-checkpoint-inhibitors
Y Yasuda, R Fujiwara, T Oguchi, Y Komai… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
Background/Aim: Immune-related adverse events (irAEs) develop in a subset of patients
with metastatic renal cell carcinoma (mRCC) treated with immune-checkpoint-inhibitors …
with metastatic renal cell carcinoma (mRCC) treated with immune-checkpoint-inhibitors …
[PDF][PDF] Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region.
C Nieder, L Stanisavljevic… - Cancer Diagnosis …, 2024 - cancerdiagnosisprognosis.org
Background/Aim: Numerous new treatment options have been approved for metastatic renal
cell carcinoma (mRCC) in the last decade. Nevertheless, not all patients receive systemic …
cell carcinoma (mRCC) in the last decade. Nevertheless, not all patients receive systemic …